BAM
IOVA icon

Bellevue Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Bellevue Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-78
Closed -$1K – 517
2022
Q1 		$1K Sell
78
-14
-15% -$217 ﹤0.01% 514
2021
Q4 		$2K Sell
92
-7
-7% -$154 ﹤0.01% 498
2021
Q3 		$2K Hold
99
– – ﹤0.01% 522
2021
Q2 		$3K Sell
99
-9
-8% -$234 ﹤0.01% 454
2021
Q1 		$3K Sell
108
-16
-13% -$663 ﹤0.01% 515
2020
Q4 		$6K Sell
124
-41
-25% -$1.63K ﹤0.01% 392
2020
Q3 		$5K Buy
165
+38
+30% +$1.17K ﹤0.01% 388
2020
Q2 		$3K Hold
127
– – ﹤0.01% 479
2020
Q1 		$5K Buy
127
+52
+69% +$1.38K 0.01% 387
2019
Q4 		$2K Buy
+75
New +$1.71K ﹤0.01% 438

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return